All the Drug Class Drugs
Proteasome Inhibitor. Bortezomib 3.5 mg. VIAL (pwdr. for sol. for inj. SC IV):1×3.5mg.
Initial. is 1.3 mg/m2. may be admin. IV at a concent. of 1 mg/mL, or SC at a concent. of 2.5 mg/mL. When admin. IV, Bortezomib is admin. as a 3 -5 second bolus IV inj. Not for intrathecal use. See lit.
Tmt. of pts. with multip.myeloma. Tmt. of pts. with mantle cell lymphoma who have received at least one prior ther. Bortezomib in comb. with rituximab, cyclophosphamide, doxorubicin and prednisone- tmt. of adult pts. with prev. untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplant.
C/I: Pts. with hypersens. (not includ. local react.), anaphylactic react. to bortezomib, boron, or mannitol. Pts. with acute diffuse infiltrative pulmon. and pericard. dis. Intrathecal admin. (due to fatal events).
Proteasome Inhibitor. Carfilzomib 60 mg/vial. SINGLE USE VIALS (Pwdr. for sol. for
inject.): I.V. over 2 to 10 min., on Days 1,
2, 8, 9, 15, 16, foll. by a rest period from
Days 17 to 28. Ea. 28day period is 1 tmt
cycle. In Cycle 1, a dose is 20 mg/m².
Dose must be indiv. adjust. accord.
with med. cond. and param. Modify
dos. based on toxic.
Tmt. of pts. with multiple myeloma who
have receiv. at least 2 prior ther. incl.
bortezomib and an immunomodul. ag.
and have demonstr. dis. progress. on or
within 60 days of compl. the last ther.
Appr. is based on response rate. Clinical
benefit, such as impr. in surv./sympt., has
not been verified.
Proteasome Inhibitor. Bortezomib 3.5 mg. VIAL (pwdr for sol.): 1. Initial: 1-3 mg/m2 2
x wkly for 2 wks (days 1, 4, 8, and 11)
foll. by 10 day rest period (days 12-21).
This 3 wk. period is a tmt. cycle. At
least 72 hrs. should elapse betw.
consec. doses. See lit.
Myeloma in pts. who have receiv. at least
two prior therapies and have shown
disease progress. on the last ther.
C/I: Hypersens., severe hepat. impair.